KMT2A and acute myeloid leukemia: Both PFS and OS rates were higher in AML patients with RUNX1::RUNX1T1, CBFB::MYH11, and biCEBPA, while the PFS and OS rates were lower for patients with MLLT3::KMT2A and GATA2::MECOM according to the 4th WHO classification (Figure 2A).